Illumina, Inc. (NASDAQ:ILMN) today appointed Mark Lewis as Senior Vice President of Development. In this newly created role, Mark is responsible for overseeing Illumina’s global product development efforts and will report to Joel McComb, Senior Vice President and General Manager of Illumina’s Life Sciences Business.

Mark joins Illumina from Becton Dickinson Biosciences where he held numerous executive, business development, and general management positions, including his most recent position as Vice President of Special Order Research Products. In this role, Mark managed the development of customized flow cytometers, evaluated multiplex clinical platforms, managed bioimaging and reagent products, and led integration and divestiture initiatives. Prior to Becton Dickinson, Mark was President of Aeomecia where he led research initiatives and commercial release of genomic technologies for gene discovery, gene characterization, and disease profiling. From 1992 to 2002, Mark held various technical, commercial, and management positions at Molecular Dynamics, including Vice President of Sequencing Technology. In that capacity, he led research and development efforts in DNA sequencing and Genotyping. Mark earned a Bachelor of Arts degree in Biology from the University of California, San Diego.

“Mark brings to Illumina more than 15 years of experience in managing product development and commercialization efforts in the life sciences market,” said Joel McComb. “His career experience in sequencing and genomics technologies will help us further shape and drive our development strategies.”